致癌性ZEB2激活驱动T细胞急性淋巴细胞白血病对KDM1A抑制的敏感性
ZEB2高表达与多种癌症不良预后相关,在小鼠模型中可驱动未成熟T-ALL。本研究鉴定KDM1A为ZEB2的新互作伙伴,证实在ZEB2水平升高的鼠和人类T-ALL中,KDM1A活性对存活至关重要;靶向ZEB2-KDM1A互作或抑制KDM1A去甲基化酶活性可能成为该侵袭性白血病亚型的新治疗策略。
要点
- ZEB2是未成熟T-ALL的致癌驱动因子,其高表达与不良预后相关。
- KDM1A被鉴定为ZEB2的新互作伙伴。
- ZEB2增高的鼠和人类T-ALL存活关键依赖KDM1A活性。
核心结论
- 通过直接破坏ZEB2-KDM1A互作或药理学抑制KDM1A去甲基化酶活性来靶向ZEB2蛋白复合物,可能成为该侵袭性人类白血病亚型及其他ZEB2驱动恶性肿瘤的新治疗策略。
研究设计与样本
- 研究使用条件性功能获得小鼠模型,并分析小鼠和人类T-ALL样本。
主要发现
- ZEB2高表达与多种人类癌症亚型的不良预后和患者结局相关。
- 在条件性功能获得小鼠模型中,ZEB2被证实为未成熟T-ALL的致癌驱动因子。
- KDM1A被鉴定为ZEB2的新互作伙伴。
- ZEB2水平升高的鼠和人类T-ALL生存关键依赖KDM1A活性。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Elevated expression of the Zinc finger E-box binding homeobox transcription factor-2 (ZEB2) is correlated with poor prognosis and patient outcome in a variety of human cancer subtypes. Using a conditional gain-of-function mouse model, we recently demonstrated that ZEB2 is an oncogenic driver of immature T-cell acute lymphoblastic leukemia (T-ALL), a heterogenic subgroup of human leukemia characterized by a high incidence of remission failure or hematological relapse after conventional chemotherapy. Here, we identified the lysine-specific demethylase KDM1A as a novel interaction partner of ZEB2 and demonstrated that mouse and human T-ALLs with increased ZEB2 levels critically depend on KDM1A activity for survival. Therefore, targeting the ZEB2 protein complex through direct disruption of the ZEB2-KDM1A interaction or pharmacological inhibition of the KDM1A demethylase activity itself could serve as a novel therapeutic strategy for this aggressive subtype of human leukemia and possibly other ZEB2-driven malignancies.
引用
- Goossens S, Peirs S, Van Loocke W, et al. Oncogenic ZEB2 activation drives sensitivity toward KDM1A inhibition in T-cell acute lymphoblastic leukemia. Blood. 2017. PMID: 28069602. doi:10.1182/blood-2016-06-721191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。